You are here

  • Home
  • Online First
  • Reassessing the evidence: does CBT truly benefit individuals with treatment-resistant schizophrenia?

Article Text

Article menu
Download PDFPDF
Mental health
Reassessing the evidence: does CBT truly benefit individuals with treatment-resistant schizophrenia?

https://doi.org/10.1136/ebnurs-2024-104175

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests OA: Disclosure 2024 Advisory Board/Consultant for Janssen-Ortho (Johnson & Johnson), Otsuka, Lundbeck, Allergan/Abbvie and Mylan/Viatris; Teva Speaking engagements: Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka, Mylan/Viatris, HLS therapeutics and Allergan/Abbvie; Research contracts: Janssen-Ortho (Johnson & Johnson), Lundbeck, Otsuka and Boehringer Ingelheim.

    • Provenance and peer review Commissioned; internally peer reviewed.